GlassScriptPhysician profile
Shazia Raza
NPI 1831176189
$4,576.66
in general payments reported to CMS, 2019-2025
20 companies · $803 in 2025
The $803 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $177 · 2021: $405 · 2022: $761 · 2023: $857 · 2024: $1,311 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,927 · Education: $43.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,927.25 |
| Education | $43.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,038.82 | 2020-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $993.83 | 2019-2025 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $518.07 | 2022-2025 | Jardiance |
| Amgen INC. | $336.27 | 2024-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $307.22 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $287.47 | 2020-2022 | |
| Horizon Therapeutics Plc | $256.66 | 2020-2023 | Krystexxa |
| Lilly USA, LLC | $110.29 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $109.19 | 2023-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $105.53 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $96.33 | 2024-2025 | |
| Daiichi Sankyo INC. | $95.43 | 2022-2024 | Injectafer |
| Fresenius USA Marketing, INC. | $92.72 | 2021-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $73.68 | 2021-2025 | Benlysta |
| Harmony Biosciences LLC | $42.75 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $30.31 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $26.84 | 2019 | |
| Shire North American Group INC | $21.80 | 2019 | |
| Opko Pharmaceuticals, LLC | $19.77 | 2024 | Rayaldee |
| Apellis Pharmaceuticals, INC. | $13.68 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shazia Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.